Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.51 |
| ▸ | ACHE | P22303 | 5/20 | 0.49 |
| ▸ | SCD | O00767 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7550044 | 0.85 | ACHE (0.65) | HRH4ACHEHDAC6CCR2CHEK2 | |
| SCHEMBL7548588 | 0.85 | ACHE (0.49) | ACHEHDAC6CCR2CHEK2 | |
| SCHEMBL7549395 | 0.84 | ACHE (0.50) | ACHEHDAC6CCR2CHEK2 | |
| Hydrochloric Acid SCHEMBL7157090 | 0.83 | ACHE (0.56) | ACHEHDAC6CHEK2 | |
| SCHEMBL7550196 | 0.83 | HDAC6 (0.49) | ACHEHDAC6CCR2CHEK2 | |
| SCHEMBL7548311 | 0.82 | DPP7 (0.53) | ACHEHDAC6CCR2CHEK2 | |
| SCHEMBL7554506 | 0.82 | ACHE (0.62) | ACHE | |
| SCHEMBL7553785 | 0.82 | CCR2 (0.62) | ACHEHDAC6PTGDR2CCR2CHEK2 | |
| SCHEMBL7553596 | 0.80 | HPSE (0.48) | ACHEHDAC6PTGDR2CCR2 | |
| SCHEMBL7546972 | 0.79 | ACHE (0.55) | HRH4ACHEHDAC6CCR2CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2002-07-25 | — | — | US | claimed |
| US-6184235-B1 | MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) ANTAGONIST FOR TREATMENT OF INFLAMMATORY DISEASES, ATHEROSCLEROSIS, RESTENOSIS, AUTOIMMUNE DISEASES, ORGAN TRANSPLANT REJECTION IN MAMMALS | WARNER-LAMBERT COMPANY | 2001-02-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | CCR1, CCR2, CCR8 | HRH4 76/4885ACHE 4652/4885SCD 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.